Peptide comparisons.
Side-by-side, evidence-based head-to-heads — mechanism, efficacy, safety, and which to choose. Sourced from trials and primary data, not marketing copy.
-
BPC-157 vs TB-500 ›
Two recovery peptides compared — mechanism, what the human evidence does (and does not) show, safety, and whether stacking is worth it.
-
Retatrutide vs Tirzepatide ›
Retatrutide's Phase 3 results, now published in NEJM and The Lancet, are the largest weight losses any obesity drug has reported, and they are not numbers anyone can act on yet. It is unapproved, the application has not been filed, and the trial that compares it directly with tirzepatide has not reported.
-
Semaglutide vs Liraglutide ›
Only one trial has ever compared these two drugs head to head for weight loss, and semaglutide won it by a factor of two and a half over 68 weeks. Then the patents moved: liraglutide now has eleven approved generics and semaglutide has none.
-
Sermorelin vs Ipamorelin ›
Sermorelin and ipamorelin both make the pituitary release growth hormone, through two different receptors, which is why clinics so often sell them together. Neither has been tested in a large trial in adults. They differ most in law: sermorelin can be compounded with a prescription, ipamorelin has no route through a 503A pharmacy at all.
-
Sermorelin vs Tesamorelin ›
Both molecules copy the hormone the hypothalamus uses to switch on growth hormone, and both act on the same receptor. Tesamorelin has two Phase 3 trials and a current FDA label for one narrow use. Sermorelin has a withdrawn approval, very little adult data, and the one thing tesamorelin lacks: a legal route through a compounding pharmacy.
-
Tesamorelin vs Ipamorelin ›
Tesamorelin and ipamorelin both raise growth hormone, through different receptors, and both are sold by clinics for body composition. That is where the resemblance ends. Tesamorelin has two Phase 3 trials and a current FDA label. Ipamorelin was never approved and missed its endpoint in the one trial that reported. And neither can be lawfully compounded.
-
Tirzepatide vs Semaglutide ›
Tirzepatide wins on weight loss by about 6.5 points in the only head-to-head trial and costs more as a branded drug; compounded, the gap moves with the sellers counted. SURMOUNT-5, the side-effect picture, and what the two actually cost.
-
Wegovy pill vs injection ›
The Wegovy tablet, approved in December 2025, is 25 mg taken every morning on an empty stomach. The injection is 2.4 mg once a week. The tablet needs ten times the milligrams because almost none of it is absorbed, and in its trial it produced 13.6% weight loss against the injection's 14.9% in a separate trial.
-
Wegovy vs Ozempic ›
Both are semaglutide from Novo Nordisk. Ozempic is the diabetes product and stops at 2 mg a week; Wegovy is the weight product and goes to 2.4 mg, with a 7.2 mg strength above that and, since December 2025, a daily tablet. The approved uses, the doses, the trials and what each costs.
-
Zepbound vs Mounjaro ›
Zepbound and Mounjaro are the same molecule, tirzepatide, from the same company, in the same strengths and the same devices. What differs is the approved use, and everything that follows from it: which trials sit behind each label, who prescribes which, and what insurance will pay for.